Bortezomib Improves EFS, OS in T-Cell Lymphoblastic Lymphoma
Bortezomib improved event-free survival and overall survival in children and young adults with T-cell lymphoblastic lymphoma.
Lymphoma
Mosunetuzumab Induced Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas
Researchers sought to determine the dose and safety profile for mosunetuzumab administered for patients with aggressive and indolent relapsed or refractory B-NHLs.
Brentuximab Vedotin With Bendamustine Appears Safe, Effective in Pediatric Patients With Relapsed/Refractory Hodgkin Lymphoma
Researchers sought to determine whether brentuximab vedotin with bendamustine would be effective in pediatric patients with relapsed or refractory Hodgkin lymphoma.
Bone Marrow Infiltration a Risk Factor for Infusion-Related Reactions in B-Cell NHL
A retrospective study of patient data sought to determine if bone marrow infiltration is linked to adverse effect severity in patients with CD20-positive B-NHL.
Isatuximab Yields No Responses in Patients With T Cell-Acute Lymphoblastic Leukemia or T Cell-Lymphoblastic Lymphoma
Researchers sought to determine whether isatuximab would have responses in patients with T-ALL or T-LBL.
New Approach May Predict Failure With CAR-T Cells for Patients With Large B-Cell Lymphoma
Researchers sought to determine whether the early use of FDG PET may help predict future failure with CAR-T therapy in patients with LBCL.
Modern Radiotherapy Techniques May Lessen, but Not Remove, Long-Term Morbidities
Researchers sought to determine whether using LF-radiotherapy would reduce excess long-term morbidity among patients with stage I-IIa classical Hodgkin lymphoma.
Health-Related Quality of Life With Pembrolizumab in Patients With Classical Hodgkin Lymphoma
Researchers sought to determine the health-related quality of life of patients with classical Hodgkin lymphoma receiving pembrolizumab.
Central Nervous System Relapse of Lymphoma Is Not Impacted by Prophylaxis Method
Researchers sought to determine whether the route of prophylaxis would impact CNS relapse in patients with certain aggressive B-cell non-Hodgkin lymphomas.
Allogeneic Transplant and CAR-T Therapy Yield Durable Remissions After Autologous Transplant Failure in DLBCL
Researchers sought to determine whether CAR-T therapy with alloHCT would lead to durable remissions in patients with DLBCL who relapsed after prior autoHCT.
- Loading...
Loading...
Loading... 
Loading...